Omalizumab to Accelerate a Symptom-driven Multi-food OIT

NCT04045301 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Food IgE-mediated Allergy
Immunotherapy
Omalizumab
Physiological Effects of Drugs

Interventions

BIOLOGICAL: Omalizumab 16mg/kg
BIOLOGICAL: Omalizumab 8mg/kg
BIOLOGICAL: Placebo
OTHER: Multi-food oral immunotherapy (OIT)

Sponsor

Philippe Bégin

Collaborators

[object Object]
[object Object]
[object Object]